title: Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.
abstract: Although antibiotics treat bacteremia in inhalational anthrax, pathogenesis is mainly driven by bacterial exotoxins. Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monkey models of inhalational anthrax. To assess raxibacumab's added benefit over levofloxacin (LVX) alone, rabbits surviving to 84 h after a challenge with 200 times the median (50%) lethal dose of B. anthracis spores were randomized to receive 3 daily intragastric LVX doses of 50 mg/kg of body weight, with the first LVX dose administered just prior to administration of a single intravenous dose of placebo or 40 mg/kg raxibacumab. The percentages of animals alive at 28 days following the last LVX dose were compared between the 2 treatment groups using a two-sided likelihood-ratio chi-square test. The 82% survival rate for the LVX-raxibacumab combination was higher than the 65% survival rate for LVX alone (P=0.0874). There were nearly 2-fold fewer deaths for the combination (7 deaths; n=39) than for LVX alone (13 deaths; n=37), and the survival time was prolonged for the combination (P=0.1016). Toxin-neutralizing-activity titers were similar for both treatment groups, suggesting that survivors in both groups were able to mount a toxin-neutralizing immune response. Microscopic findings considered consistent with anthrax were present in animals that died or became moribund on study in both treatment groups, and there were no anthrax-related findings in animals that survived. Overall, raxibacumab provided a meaningful benefit over antibiotic alone when administered late in the disease course.
authors.affiliation: Human Genome Sciences, Inc., Rockville, Maryland, USA.
authors.forename: Thi-Sau
authors.initials: TS
authors.lastname: Migone
authors.affiliation: Human Genome Sciences, Inc., Rockville, Maryland, USA.
authors.forename: Sally
authors.initials: S
authors.lastname: Bolmer
authors.affiliation: Human Genome Sciences, Inc., Rockville, Maryland, USA.
authors.forename: John
authors.initials: J
authors.lastname: Zhong
authors.affiliation: Human Genome Sciences, Inc., Rockville, Maryland, USA alfred.x.corey@gsk.com.
authors.forename: Al
authors.initials: A
authors.lastname: Corey
authors.affiliation: Battelle Biomedical Research Institute, Columbus, Ohio, USA.
authors.forename: Daphne
authors.initials: D
authors.lastname: Vasconcelos
authors.affiliation: Battelle Biomedical Research Institute, Columbus, Ohio, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Buccellato
authors.affiliation: Battelle Biomedical Research Institute, Columbus, Ohio, USA.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Meister
mesh_terms: D000818:Animals; D000881:Anthrax / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D064704:Levofloxacin / Q000627:therapeutic use; D008297:Male; D011817:Rabbits; D012141:Respiratory Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D064704:Levofloxacin; C542124:raxibacumab